Edition

Benjamin Y. Fong

2

0

Honors Faculty Fellow, Associate Teaching Professor, and Associate Director of the Center for Work & Democracy, Arizona State University

A growing body of evidence points to MDMA’s therapeutic potential for managing an array of hard-to-treat conditions like PTSD and depression. Antonio Ciufo/Moment via Getty Images

August 12, 2024

FDA rejects MDMA‑assisted therapy for PTSD treatment – a drug researcher explains the challenges psychedelics face

Benjamin Y. Fong, Arizona State University

The FDA’s decision shines a light on some of the unique obstacles that psychedelic drugs may face on the path to approval.

Psilocybin mushrooms have been approved for therapeutic use in Oregon and Colorado. The Washington Post /Contributor via Getty Images

August 2, 2024

Psilocybin legislation is helping psychedelic drugs make a comeback – a drug researcher explains the challenges they face

Benjamin Y. Fong, Arizona State University

Pharmaceutical giants like Johnson & Johnson as well as smaller startups are investing in psychedelic drug development, and both are pursuing FDA approval for their patented psilocybin formulations.

Contact Benjamin for

General
Media request
Speaking request
Consulting / Advising
Research collaboration
Research supervision

Location: Tempe, Arizona, U.S.
Website
Article Feed
Joined July 2, 2024